CLONIPAIN: Intraoperative Clonidine for Postoperative Pain Management in Patients Undergoing Surgical Treatment for Endometriosis

Sponsor
University of Aarhus (Other)
Overall Status
Recruiting
CT.gov ID
NCT05560230
Collaborator
Aarhus University Hospital (Other)
120
1
2
22.9
5.2

Study Details

Study Description

Brief Summary

The role of a single dose of intraoperative clonidine on postoperative opioid requirements, pain intensity and opioid-related side effects in patients undergoing surgical treatment for endometriosis remains scarcely explored. A prospective double-blind, randomised controlled trial investigating the effect of a single-dose of intraoperative clonidine in patients undergoing surgical treatment for endometriosis is therefore conducted.

Condition or Disease Intervention/Treatment Phase
Phase 4

Detailed Description

Background with aim: Acute postoperative pain is a major and common concern for the large number of patients who undergo surgery each year. Despite advances in pain management strategies, many patients continue to suffer from moderate-to-severe pain during the early postoperative period. This is concerning as unrelieved pain can result in decreased patient satisfaction, increased morbidity, prolonged hospital length-of-stay and increased risk of persistent pain. Effective treatment of acute postoperative pain should therefore be prioritized. Opioid analgesics remain the mainstay treatment for postoperative pain. The potential benefits of opioid therapy for acute pain are short-term pain control. However, there are several potential harms associated with opioid use which may outweigh the benefits including sedation, nausea, vomiting, constipation and risk of long-term use. In this respect, a single dose of clonidine could provide stable analgesia and potentially reduce the need for shorter-acting opioids. Therefore, the investigators decided to carry out the present study with the aim to examine the analgesic efficacy and safety of intraoperatively administered intravenous clonidine in patients undergoing surgical treatment for endometriosis on postoperative opioid consumption, pain intensity and opioid-related side effects.

Method: 120 patients undergoing surgical treatment for endometriosis will be included in this prospective, randomized, double-blind, controlled trial with two arms: an intervention arm (clonidine 150 microgram) and a control arm (isotonic saline). The study will be GCP-monitored, and is approved by the Danish Medicines Agency (2022064017) and the National Committee on Health Research Ethics (2209269).

Hypothesis: The investigators hypothesize that a single dose of intraoperatively administered intravenous clonidine will be effective in reducing postoperative opioid requirements, pain intensity and opioid-related side effects.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
120 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
120 patients undergoing surgical treatment for endometriosis will be included in this prospective, randomized, double-blind, controlled trial with two arms: Intervention arm (clonidine 150 microgram). Control arm (isotonic saline).120 patients undergoing surgical treatment for endometriosis will be included in this prospective, randomized, double-blind, controlled trial with two arms: Intervention arm (clonidine 150 microgram). Control arm (isotonic saline).
Masking:
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Masking Description:
Randomization and study medication will be handled by the hospital pharmacy. All research team members, caregiving clinicians and enrolled patients will be blinded to the study allocation arms and the randomisation list will be concealed until all statistical analyses are made.
Primary Purpose:
Treatment
Official Title:
Intraoperative Clonidine for Postoperative Pain Management in Patients Undergoing Surgical Treatment for Endometriosis: a Prospective, Double-blind, Randomized Controlled Trial
Actual Study Start Date :
Oct 3, 2022
Anticipated Primary Completion Date :
Oct 3, 2022
Anticipated Study Completion Date :
Aug 31, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: Clonidine

A 100 ml isotonic saline will be mixed with 1 ml clonidine (150 μg). The blinded 100 ml bag including isotonic saline and clonidine 150 μg will be infused over 5-10 min., immediately after intubation.

Drug: Clonidine
A single dose of intraoperatively administered intravenous clonidine 150 μg will be infused over 5-10 min., immediately after intubation

Placebo Comparator: Isotonic saline

A 100 ml isotonic saline will be mixed with 1 ml isotonic saline. The blinded 100 ml bag including isotonic saline will be infused over 5-10 min., immediately after intubation.

Drug: Isotonic saline
A single dose of administered intravenous isotonic saline will be infused over 5-10 min., immediately after intubation

Outcome Measures

Primary Outcome Measures

  1. Cumulative opioid consumption 0-3 hours [3 hours after arrival at the PACU]

    Opioid consumption within the first 3 hours after arrival at the PACU

Secondary Outcome Measures

  1. Cumulative opioid consumption 0-6 hours [6 hours after arrival at the PACU]

    Opioid consumption within the first 6 hours after arrival at the PACU

  2. Pain intensity at rest [0, 30, 60, 90 and 120 minutes after arrival at the PACU]

    Pain intensity at rest (NRS; 0-10) at 0, 30, 60, 90 and 120 minutes after arrival at the PACU

  3. Pain intensity during coughing [0, 30, 60, 90 and 120 minutes after arrival at the PACU]

    Pain intensity during coughing at 0, 30, 60, 90 and 120 minutes after arrival at the PACU

  4. Shivering [0, 60 and 120 minutes after arrival at the PACU]

    Shivering at 0, 60 and 120 minutes after arrival at the PACU

  5. Sedation (Ramsey Sedation Score 1-6) [0, 60 and 120 minutes after arrival at the PACU]

    Sedation at 0, 60 and 120 minutes after arrival at the PACU

  6. PONV [0, 60 and 120 minutes after arrival at the PACU]

    Nausea and/or vomiting at 0, 60 and 120 minutes after arrival at the PACU

  7. Discharge from the PACU [24 hours]

    Time for discharge from the PACU (hours and minutes)

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 110 Years
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:

• Patients scheduled for surgical laparoscopic treatment of endometriosis at Aarhus University Hospital

Exclusion Criteria:
  • Age < 18 years

  • American Society of Anesthesiologists (ASA) physical status IV or V

  • Allergy to clonidine

  • Inability to provide informed consent

  • Known severe renal insufficiency

  • Known severe bradyarrhythmia

  • Pregnancy, lactation:

  • Daily opioid consumption the last 7 days before surgery

  • Pain intensity >5 on more than half of the days during the last month

Contacts and Locations

Locations

Site City State Country Postal Code
1 Aarhus University Hospital Aarhus Denmark 8000

Sponsors and Collaborators

  • University of Aarhus
  • Aarhus University Hospital

Investigators

  • Study Chair: Lone Nikolajsen, MD, DMSc, Aarhus University Hospital

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
University of Aarhus
ClinicalTrials.gov Identifier:
NCT05560230
Other Study ID Numbers:
  • 2022064017
First Posted:
Sep 29, 2022
Last Update Posted:
Oct 10, 2022
Last Verified:
Sep 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Oct 10, 2022